Thomas Sonderman

🧬 Interested in pharma, biotech and medical device news? Visit PharmaDeviceNews.com →

Business news, market intelligence, and global industry analysis.

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

IonQ’s $1.8 billion acquisition of SkyWater Technology gives the quantum computing company control of a Pentagon-accredited semiconductor foundry, while raising fresh questions over capital intensity, integration risk and persistent losses. Representative image.

IonQ closes $1.8bn SkyWater deal after FTC splits 1-1 on quantum conditions

IonQ closed the $1.8bn SkyWater buy after a 1-1 FTC split, gaining a Pentagon-accredited US foundry ahead of an Aug 5 earnings call that now matters more.

bySrinath

August 2, 2026

IonQ clears final regulatory hurdle for $1.8bn SkyWater acquisition

IonQ has cleared the final hurdle for its $1.8 billion SkyWater deal, but foundry integration, cash burn and quantum milestones remain the real test.

bySrinath

July 29, 2026

The Latest

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

IonQ closes $1.8bn SkyWater deal after FTC splits 1-1 on quantum conditions

IonQ clears final regulatory hurdle for $1.8bn SkyWater acquisition

Acumen Pharmaceuticals faces strategic reset with $78.6m cash after Alzheimer’s drug failure

NRx Pharmaceuticals moves toward ketamine sales after FDA approval of domestic injectable product

Intellect Design Arena (INTELLECT) near Rs 505: Is the 16% share-price crash justified when AI revenue is growing but profits are not?

Affle 3i to acquire Perion for $420m, but its $228m cash balance changes the deal maths

SAMILBIO expands Chaeyun skincare with two November launches as K-beauty exports reach $11.1bn

Schneider Electric Infrastructure (SCHNEIDER) shares fall 3.5% despite new factory expansion: What will November results reveal?

Haleon (HLN) near 319p: Does a 15% share-price crash make its valuation attractive after the growth downgrade?

Ethan Allen will split CEO and chair roles, but who gets to choose Farooq Kathwari’s successor?